Category: CDE

Categories
CDE Diabetes

Study Guide: Treatment of Diabetes in People with Heart Failure (Chapter 28)

1. Overview & Pathophysiology

Heart failure (HF) is a frequent and serious comorbidity in diabetes.

  • Incidence: The incidence of heart failure is 2- to 4-fold higher in people with diabetes compared to those without.
  • Diabetic Cardiomyopathy: Diabetes can cause heart failure independently of coronary artery disease or hypertension. This is known as “diabetic cardiomyopathy”.
  • Types: Heart failure can occur with Reduced Ejection Fraction (HFrEF, LVEF <40%) or Preserved Ejection Fraction (HFpEF, LVEF >50%).

2. Diagnosis

Diagnosis relies on typical signs/symptoms (edema, shortness of breath) combined with objective evidence (Echo, Chest X-ray).

  • Biomarkers: Brain Natriuretic Peptide (BNP) or NT-pro-BNP are useful to aid diagnosis when clinical uncertainty exists.
  • Screening: Current evidence is mixed, and there is no clear consensus to routinely screen asymptomatic people with diabetes for HF using BNP testing.

3. Antihyperglycemic Agents & Heart Failure (High Yield)

The choice of diabetes medication is critical in this population. You must know which drugs help, which are neutral, and which can harm.

A. The “Good” (Benefit demonstrated)

  • SGLT2 Inhibitors:
    • Empagliflozin: Demonstrated a 35% reduction in heart failure hospitalization in the EMPA-REG OUTCOME trial.
    • Canagliflozin: Reduced heart failure hospitalization in the CANVAS trial.
    • Mechanism: Benefits appear independent of glucose lowering.
    • NOTE: This guideline chapter was published prior to the EMPEROR-REDUCED (Empagliflozin) and DAPA-HF (Dapagliflozin) trials were published

B. The “Neutral” (Generally Safe)

  • Metformin:
    • Safe and effective. Studies show people with HF fare as well or better on Metformin than other agents.
    • Caveat: Use with caution in renal dysfunction (eGFR > 30 mL/min is generally safe) and stop if acute illness/dehydration occurs.
  • GLP-1 Receptor Agonists:
    • Liraglutide (LEADER), Lixisenatide (ELIXA), and Semaglutide (SUSTAIN-6) showed neutrality for heart failure hospitalization.
    • Note: Liraglutide showed no benefit in patients with established HFrEF (FIGHT study).

C. The “Bad” / Caution Required (Potential Harm)

  • Thiazolidinediones (TZDs):
    • Rosiglitazone & Pioglitazone: Cause fluid retention. Rosiglitazone doubled the risk of HF death/hospitalization in the RECORD trial.
    • Contraindication: Avoid in people with NYHA Class I–IV heart failure.
  • DPP-4 Inhibitors (Saxagliptin):
    • Saxagliptin: The SAVOR-TIMI 53 trial showed an increased risk of hospitalization for heart failure.
    • Warning: Health Canada and FDA issued warnings to consider discontinuing Saxagliptin if HF develops.
    • Other DPP-4s: Sitagliptin (TECOS) and Alogliptin (EXAMINE) were neutral.

4. Heart Failure Medications in Diabetes

People with diabetes should receive the same standard HF therapies as those without diabetes.

  • Beta-Blockers: Carvedilol, Bisoprolol, and Metoprolol Succinate reduce mortality.
    • CDE Pearl: Carvedilol may improve glycemic control compared to other beta-blockers.
  • RAAS Blockade (ACEi/ARB/ARNI): Effective but requires monitoring.
    • Risk: People with diabetes are at higher risk for hyperkalemia and worsening renal function.
    • Management: Halve the starting dose and monitor electrolytes/creatinine within 7–10 days of initiation.

5. 2018 Diabetes Canada Clinical Practice Guidelines Recommendations

Key takeaways from the “Recommendations” section (Page S200).

  1. Standard of Care: Individuals with diabetes and heart failure should receive the same heart failure therapies (ACEi, Beta-blockers, etc.) as those without diabetes [Grade D, Consensus].

  2. Metformin: May be used in people with T2D and heart failure (unless contraindicated/renal failure) [Grade C, Level 3]. Stop if renal function significantly worsens [Grade D].

  3. Avoid TZDs: For people with NYHA class I–IV, exposure to TZDs should be avoided [Grade A, Level 1].

  4. SGLT2 Inhibitors: In adults with T2D and clinical CVD (and eGFR > 30), an SGLT2 inhibitor with demonstrated benefit may be added to reduce the risk of heart failure hospitalization.

  5. Dosing Caution: In adults with diabetes and HF with eGFR < 60 mL/min, starting doses of ACEi or ARBs should be halved [Grade D, Consensus].

Reference:

Connelly KA, Gilbert RE, Liu P. Treatment of Diabetes in People With Heart Failure. Canadian Journal of Diabetes. 2018;42:S196-S200. doi:10.1016/j.jcjd.2017.10.026
Categories
CDE Diabetes

Flashcards: Management of Acute Coronary Syndromes (Chapter 27)

Despite advances in cardiac care, individuals with diabetes presenting with Acute Coronary Syndromes (ACS) remain at a higher risk for mortality and heart failure compared to those without diabetes. Paradoxically, these patients are often less likely to receive evidence-based interventions. These flashcards are designed to help pharmacists and healthcare professionals quickly recall the 2018 Clinical Practice Guidelines regarding the management of acute hyperglycemia, the use of invasive strategies, and essential pharmacotherapy.

Key Topics Covered:

  • The “Treatment Gap”: Memorizing the evidence that people with diabetes are statistically less likely to receive thrombolysis, revascularization, and cardioprotective medications despite having worse prognoses.

  • Glycemic Targets: Recalling the specific protocol for managing hyperglycemia (random glucose >11.0 mmol/L) during ACS, with a target range of 7.0–10.0 mmol/L.

  • Pharmacotherapy: Identifying the indications for Dual Antiplatelet Therapy (DAPT), ACE inhibitors, and beta-blockers in the post-MI setting.

  • Invasive Strategies: Understanding the clear benefits of early angiography and revascularization over medical management alone for this population.

  • Risk Stratification: Recognizing admission hyperglycemia as an independent predictor of short- and long-term mortality.

Categories
CDE Diabetes

Practice Exam: Management of Acute Coronary Syndromes (Chapter 27)

While the rates of acute myocardial infarction have decreased over the last two decades, the burden of disease remains disproportionately high for people with diabetes. The 2018 Clinical Practice Guidelines highlight a concerning paradox: despite having a higher risk of mortality and recurrent events, individuals with diabetes are often less likely to receive evidence-based therapies such as early invasive strategies and dual antiplatelet therapy.

This practice exam tests your ability to identify these treatment gaps and apply the specific protocols for glycemic management during an acute coronary event.

Key Concepts Covered in This Exam:

  • Prognostic Indicators: Understanding that diabetes and acute hyperglycemia are independent predictors of short- and long-term mortality, recurrent MI, and heart failure.

  • The “Treatment Gap”: Recognizing that patients with diabetes are statistically less likely to receive recommended interventions—including revascularization, fibrinolysis, and beta-blockers—compared to those without diabetes.

  • Acute Glycemic Control: Mastering the protocol for patients presenting with hyperglycemia (random glucose >11.0 mmol/L) and the target range of 7.0–10.0 mmol/L to improve outcomes.

  • Pharmacotherapy: Applying recommendations for the use of dual antiplatelet therapy (DAPT) and ACE inhibitors in the high-risk post-MI population.

  • Revascularization Strategies: Understanding the importance of promoting adherence to invasive strategies when indicated, rather than deferring due to diabetes status.

1. Case: A patient with diabetes and NSTE-ACS with high-risk features is being managed. What strategy is recommended for revascularization?

2. Case: A patient with type 2 diabetes is hospitalized with ACS. Their blood glucose during the first 24 hours averages 14 mmol/L. Based on the guidelines, what is the clinical significance?

3. Case: A clinical team is discussing whether FPG alone is adequate for diagnosing diabetes in ACS patients. Based on the evidence, what is accurate?

4. The guidelines note that despite the decrease in MI rates, the burden of MI in people with diabetes continues to rise. What is the primary reason?

5. Compared to individuals without diabetes, people with diabetes have what increased risk of acute coronary syndrome?

6. According to the guidelines, what fraction of people with MI have either diabetes or prediabetes?

7. What is the target blood glucose range for people with ACS and hyperglycemia according to Diabetes Canada?

8. For prasugrel use in people with diabetes and ACS, which patient characteristic is a contraindication according to the guidelines?

9. Case: A healthcare team is reviewing why people with diabetes have worse outcomes after ACS. According to the guidelines, which factor contributes to adverse outcomes?

10. Case: A quality improvement team is reviewing care gaps. According to the guidelines, people with diabetes are less likely to receive which treatments compared to people without diabetes?

11. Case: A 62-year-old man with type 2 diabetes presents with NSTE-ACS and is undergoing PCI. He is clopidogrel naïve, weighs 75 kg, is 68 years old, and has no history of stroke. Which antiplatelet agent is preferred over clopidogrel?

12. What is the frequency of previously unrecognized diabetes in the ACS population according to the guidelines?

13. What percentage reduction in acute MI rates occurred in people with diabetes between 1990 and 2010?

14. What is the increased short-term and long-term mortality risk in people with diabetes compared to those without diabetes after ACS?

15. What is the clinical significance of the finding that in-hospital mortality has a closer relationship to hyperglycemia than to diabetic status?

16. Case: A 58-year-old woman with diabetes presents with NSTE-ACS. She has complex multivessel coronary disease including the LAD. What revascularization modality is preferred?

17. According to the guidelines, at what random blood glucose level should antihyperglycemic therapy be considered in people with acute MI?

18. According to the guidelines, acute coronary events occur how many years earlier in people with diabetes compared to those without?

19. Case: A patient with diabetes and STEMI requires reperfusion. PPCI is available within 90 minutes. What is the recommendation?

20. According to the guidelines, what is one reason people with diabetes have a pro-thrombotic state?

21. Case: A patient without known diabetes is admitted with ACS. Their random plasma glucose is 12.5 mmol/L. What should be initiated?

22. A diabetes educator is explaining why clopidogrel may be less effective in some patients with diabetes. What is the evidence-based explanation?

23. At what A1C threshold should in-hospital capillary blood glucose monitoring be initiated in people without a history of diabetes admitted with ACS?

24. Case: A clinician asks why CABG is preferred over complex PCI in people with diabetes and complex coronary anatomy. What is the evidence-based rationale?

25. According to the prediction model cited in the guidelines, which factors are significantly associated with 5-year mortality after AMI in people with diabetes?

26. Case: A 65-year-old patient with diabetes has single-vessel coronary disease not involving the LAD and a SYNTAX score of 18. What revascularization approach is acceptable?

27. According to the guidelines, what percentage of people admitted with an acute coronary syndrome have known diabetes?


 

Categories
CDE Diabetes

Study Guide: Management of Acute Coronary Syndromes (Chapter 27)

1. Overview & Epidemiology

Diabetes is one of the top risk factors for myocardial infarction (MI). The relationship between diabetes and Acute Coronary Syndromes (ACS) is critical for CDEs to understand.

  • Prevalence: Approximately 30–50% of people admitted with ACS have either known diabetes or previously undiagnosed diabetes (or prediabetes).
  • Worse Outcomes: Compared to those without diabetes, people with diabetes have:
    • 3-fold increased risk of ACS.
    • Events occur 15 years earlier.
    • 2-fold increased mortality (short and long-term).
  • Care Gap: People with diabetes are historically less likely to receive guideline-recommended therapies (like early invasive strategies) despite having greater benefit from them.
     

2. Screening for Diabetes in ACS

Because stress hyperglycemia is common and undiagnosed diabetes is prevalent, specific screening protocols are recommended upon admission for ACS.

The Screening Algorithm:

  1. Measure: Admission A1C and Random Plasma Glucose (PG) in all ACS patients without a history of diabetes.
  2. Interpret:
    • A1C 6.5% OR Random PG 11.1 mmol/L: Presumed diabetes/stress hyperglycemia. Action: Start in-hospital capillary blood glucose monitoring (AC and HS for 48 hours).
    • A1C 5.5 – 6.4%: “At Risk.” Action: Rescreen after discharge .
    • A1C < 5.5%: Normal.

3. In-Hospital Glycemic Management

Hyperglycemia in the first 24–48 hours post-ACS is associated with increased mortality.

  • Target: If random BG is mmol/L, treat to maintain BG between 7.0 – 10.0 mmol/L.
  • Method: Insulin therapy is often required. The goal is to avoid both severe hyperglycemia and hypoglycemia (which can negate benefits).
  • Note: The guidelines do not recommend “tight” control (e.g., normal range) in the acute phase as evidence remains inconclusive and hypoglycemia risk is high.

4. Pharmacotherapy: Antiplatelet Agents

Platelets in people with diabetes are “hyperactive” and pro-thrombotic. Therefore, potent antiplatelet therapy is crucial.

A. ASA (Aspirin):

  • Standard of care for all ACS patients.

B. P2Y12 Inhibitors (The Second Antiplatelet):

  • Clopidogrel: A weaker inhibitor; many patients with diabetes have high residual platelet activity on Clopidogrel.
  • Ticagrelor (Brilinta) & Prasugrel (Effient): Preferred over Clopidogrel.
    • TRITON-TIMI 38 (Prasugrel): Showed a 30% reduction in primary endpoints (CV death, MI, stroke) in patients with diabetes compared to Clopidogrel.
    • PLATO (Ticagrelor): Significant reduction in CV death and MI compared to Clopidogrel.
  • Long-Term Therapy: For high-risk patients (history of MI + diabetes), extending Ticagrelor (60 mg BID) up to 3 years reduced CV death, MI, or stroke (PEGASUS-TIMI 54 trial).

5. Revascularization Strategies

How to fix the blocked arteries?

  • NSTE-ACS (Non-ST Elevation): An early invasive strategy (angiogram/intervention) is preferred over a conservative (“wait and see”) approach for people with diabetes.
  • CABG vs. PCI: For complex multi-vessel disease, Coronary Artery Bypass Grafting (CABG) is preferred over PCI (stenting) because it reduces death and MI in this specific population.
  • STEMI (ST Elevation):
    • Primary PCI: Preferred if available.
    • Fibrinolysis (Clot busters): If PCI is not available. Important Exam Note: Diabetic Retinopathy is NOT a contraindication to fibrinolysis (ocular hemorrhage is extremely rare).

6. 2018 Diabetes Canada Clinical Practice Guidelines Recommendations

Key takeaways from the “Recommendations” section (Page S192).

  1. Screening: In all people with ACS without known diabetes, measure A1C and Random PG. If A1C 6.5% or Random PG 11.1, initiate in-hospital monitoring [Grade D, Consensus].

  2. Glycemic Targets: If BG > 11.0 mmol/L, treat to target 7.0–10.0 mmol/L [Grade C, Level 2].

  3. Antiplatelet Choice: In patients with diabetes and ACS undergoing PCI, use Prasugrel [Grade A] or Ticagrelor [Grade B] rather than clopidogrel.

  4. Extended Therapy: Consider prolonged Ticagrelor (60 mg BID) for up to 3 years in high-risk patients [Grade B, Level 2].

  5. Revascularization: For complex coronary anatomy (multi-vessel), CABG should be considered rather than complex PCI [Grade A, Level 1].

  6. Fibrinolysis: Retinopathy should not be a contraindication to fibrinolysis [Grade B, Level 2].

Reference:

Tardif JC, L’Allier PL, Fitchett DH. Management of Acute Coronary Syndromes. Canadian Journal of Diabetes. 2018;42:S190-S195. doi:10.1016/j.jcjd.2017.10.029
Categories
CDE Diabetes

Flashcards: Treatment of Hypertension (Chapter 26)

Hypertension affects the majority of people with diabetes and acts as a potent multiplier for cardiovascular and microvascular complications. These flashcards are designed to help pharmacists and healthcare professionals quickly recall the 2018 Clinical Practice Guidelines regarding blood pressure thresholds, lifestyle interventions, and the specific indications for renin-angiotensin-aldosterone system (RAAS) blockade.

Key Topics Covered:

  • Therapeutic Targets: Memorizing the recommended blood pressure target of <130/80 mmHg for optimal renal and cardiovascular protection.

  • Drug Selection: Identifying when to initiate therapy with an ACE inhibitor or ARB, specifically in patients with cardiovascular disease, chronic kidney disease, or albuminuria.

  • Lifestyle Interventions: Recalling specific targets for sodium restriction (<2000 mg/day), alcohol limits, and the DASH diet.

  • Combination Therapy: Understanding the need for combination therapy (often required for most patients) and the caution against combining ACE inhibitors with ARBs.

  • Renal Protection: Reviewing the role of antihypertensive agents in delaying the progression of diabetic nephropathy.

Categories
CDE Diabetes

Practice Exam: Treatment of Hypertension (Chapter 26)

Hypertension affects the majority of people with diabetes and acts as a potent multiplier for cardiovascular and microvascular complications. The 2018 Clinical Practice Guidelines provide aggressive targets and specific pharmacotherapy algorithms to reduce the risk of stroke, myocardial infarction, and renal failure.

This practice exam tests your ability to apply the evidence-based recommendations for blood pressure thresholds, treatment initiation, and the selection of antihypertensive agents based on comorbidities.

Key Concepts Covered in This Exam:

  • Therapeutic Targets: Mastering the recommended target of <130/80 mmHg for people with diabetes to maximize renal and cardiovascular protection.

  • First-Line Therapy: Identifying the specific indications (e.g., cardiovascular disease, chronic kidney disease, albuminuria) for choosing an ACE inhibitor or Angiotensin Receptor Blocker (ARB) as initial therapy.

  • Lifestyle Interventions: Applying non-pharmacologic strategies, including sodium restriction (<2000 mg/day), the DASH diet (high fruit/vegetable/low-fat dairy intake), and alcohol moderation.

  • Treatment Algorithms: Understanding when to start with standard-dose monotherapy versus when combination therapy may be required.

  • Renal Protection: Recognizing the unique role of renin-angiotensin-aldosterone system (RAAS) blockade in delaying the progression of diabetic nephropathy.

Please go to Practice Exam: Treatment of Hypertension (Chapter 26) to view this quiz

Categories
CDE Diabetes

Study Guide: Treatment of Hypertension (Chapter 26)

1. Overview & Targets

Hypertension affects fewer than 50% of people with diabetes, yet it is a major driver of cardiovascular disease (CVD), stroke, and nephropathy. Aggressive blood pressure (BP) control is often more effective at reducing CVD events than aggressive glycemic control.

  • Diagnostic Threshold: Hypertension in diabetes is defined as 130/80 mmHg.

  • Treatment Target: The goal for essentially all adults with diabetes is < 130/80 mmHg.

    • Note: This is lower than the general population target (often <140/90).

2. Diagnosis and Measurement

  • Method: Diagnosis should be based on proper in-office measurements (averaged) or, preferably, out-of-office measurements like Ambulatory Blood Pressure Monitoring (ABPM) or home monitoring to rule out “White Coat” hypertension.

  • Assessment: At diagnosis, assess for end-organ damage (retinopathy, nephropathy) and cardiovascular risk factors.

3. Management Strategy (The Algorithm)

The choice of initial medication depends heavily on the presence of existing complications or risk factors.

A. Lifestyle Intervention (First Line for All)

  • Weight: Achieve and maintain a healthy body weight.

  • Diet:

    • Sodium: Reduce intake to < 2,000 mg/day.

    • Pattern: DASH diet (high fruits/vegetables, low-fat dairy).

    • Potassium: Dietary potassium intake should be increased (unless renal insufficiency exists).

  • Alcohol: Limit to 2 drinks/day (men) and 1 drink/day (women).

  • Activity: Accumulate 150 mins/week of moderate-to-vigorous aerobic exercise.

B. Pharmacotherapy: Initial Choice

Scenario 1: With Cardiovascular or Kidney Disease

  • Indication: If the patient has known CVD, Chronic Kidney Disease (CKD), Albuminuria, or additional CV risk factors.

  • First Line: ACE Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB).

    • Rationale: These agents provide specific renoprotection and CV risk reduction beyond just lowering BP.

Scenario 2: No Complications/Risk Factors

  • Indication: Patient has diabetes and hypertension but no albuminuria, CVD, or other major risk factors.

  • First Line Options:

    • ACE Inhibitor

    • ARB

    • Dihydropyridine CCB (e.g., Amlodipine)

    • Thiazide-like diuretic (e.g., Indapamide, Chlorthalidone).

C. Combination Therapy

Most people with diabetes will require 2 or more agents to reach the target of <130/80 mmHg.

  • If not at target: Add a second agent from a different class.

  • Preferred Combinations:

    • ACEi/ARB + DHP-CCB (Dihydropyridine Calcium Channel Blocker).

    • ACEi/ARB + Thiazide-like diuretic.

  • Caution: Do not combine an ACEi with an ARB (risk of hyperkalemia/renal failure without added benefit).

D. Beta-Blockers?

  • Beta-blockers are NOT indicated as first-line therapy for uncomplicated hypertension in diabetes.

  • Exceptions: Use them if there is a specific cardiac indication (e.g., recent Myocardial Infarction, Heart Failure).

4. Special Considerations

  • Pregnancy:

    • Contraindicated: ACE inhibitors, ARBs, and Statins must be stopped prior to conception (teratogenic).

    • Safe Agents: Methyldopa, Labetalol, Nifedipine XL.

  • Renal Monitoring: When starting ACEi/ARB, monitor serum creatinine and potassium (expect a small, acceptable rise in creatinine; watch for hyperkalemia).

  • Orthostatic Hypotension: Monitor for drops in BP upon standing, especially in the elderly or those with autonomic neuropathy.

5. 2018 Diabetes Canada Clinical Practice Guidelines Recommendations

Key takeaways from the “Recommendations” section (Page S189).

  1. Threshold & Target: People with diabetes should be treated to achieve a systolic BP < 130 mmHg [Grade C] and diastolic BP < 80 mmHg [Grade B].

  2. Initial Therapy (with complications): For persons with CVD, CKD (including albuminuria), or additional CV risk factors, an ACEi or ARB is recommended as initial therapy [Grade A, Level 1A].

  3. Initial Therapy (without complications): For others, acceptable initial choices include ACEi, ARB, DHP-CCB, or thiazide-like diuretic [Grade A to B depending on drug].

  4. Add-on Therapy: If targets are not achieved, add a second agent. If initial therapy was an ACEi/ARB, a DHP-CCB is preferred over a diuretic [Grade A, Level 1A].

  5. Pregnancy: Women trying to conceive should discontinue ACEi/ARBs [Grade D, Consensus].

Reference:

Tobe SW, Gilbert RE, Jones C, Leiter LA, Prebtani APH, Woo V. Treatment of Hypertension. Canadian Journal of Diabetes. 2018;42:S186-S189. doi:10.1016/j.jcjd.2017.10.011
Categories
CDE Diabetes

Flashcards: Dyslipidemia (Chapter 25)

Dyslipidemia is a pervasive risk factor in diabetes, requiring aggressive intervention to mitigate cardiovascular risk. These flashcards are designed to help pharmacists and healthcare professionals memorize the 2018 Clinical Practice Guidelines regarding statin initiation, specific cholesterol targets, and the management of refractory cases or severe hypertriglyceridemia.

Key Topics Covered:

  • Therapeutic Targets: Memorizing the primary goal of LDL-C consistently <2.0 mmol/L (or >50% reduction) and alternative targets like Non-HDL-C <2.6 mmol/L.

  • Statin Indications: Identifying the criteria for initiating statin therapy, such as age 40, diabetes duration >15 years, or the presence of microvascular complications.

  • Intensification: Reviewing the steps for intensifying therapy with ezetimibe or PCSK9 inhibitors when statin monotherapy fails to reach targets.

  • Hypertriglyceridemia: Understanding the specific indication for fibrates—primarily to prevent pancreatitis in patients with triglycerides >10.0 mmol/L—rather than for routine cardiovascular prevention.

  • Screening Protocols: Recalling the recommended frequency for lipid profile screening at diagnosis and during treatment follow-up.

Categories
CDE Diabetes

Practice Exam: Dyslipidemia (Chapter 25)

Dyslipidemia is one of the most significant modifiable risk factors for cardiovascular disease in people with diabetes. The 2018 Clinical Practice Guidelines simplify the management approach by focusing on statin therapy for high-risk individuals and establishing clear, aggressive targets for Low-Density Lipoprotein Cholesterol (LDL-C).

This practice exam tests your ability to identify who requires statin therapy, when to intensify treatment with second-line agents, and how to manage hypertriglyceridemia safely.

Key Concepts Covered in This Exam:

  • Indications for Statin Therapy: Identifying the broad criteria for treatment initiation, including age 40, duration of diabetes >15 years, or the presence of microvascular complications.

  • Therapeutic Targets: Mastering the primary goal of therapy: achieving an LDL-C consistently <2.0 mmol/L or a >50% reduction from baseline.

  • Intensification: Knowing when to add ezetimibe or PCSK9 inhibitors for patients who do not reach targets despite maximally tolerated statin therapy.

  • Hypertriglyceridemia: Understanding that fibrates are generally used to prevent pancreatitis when triglycerides are >10.0 mmol/L, rather than for primary CVD prevention.

  • Screening Intervals: Recalling the recommendation to screen lipid profiles at diagnosis and annually (or every 3 to 6 months after starting treatment).

Please go to Practice Exam: Dyslipidemia (Chapter 25) to view this quiz
Categories
CDE Diabetes

Study Guide: Dyslipidemia (Chapter 25)

1. Overview & Pathophysiology

Dyslipidemia is a major risk factor for cardiovascular disease (CVD) in diabetes. The lipid profile in diabetes (especially Type 2) often presents a specific “atherogenic” pattern:

  • Typical Pattern:

    • High Triglycerides (TG).

    • Low HDL-Cholesterol.

    • Normal or slightly elevated LDL-Cholesterol (but the particles are typically small, dense, and highly atherogenic).

  • Primary Goal: Lowering LDL-C is the primary target because it has the strongest evidence for CVD risk reduction.

2. Screening

  • Who: All adults with diabetes.

  • When: At diagnosis and then every 1–3 years as clinically indicated.

  • Components: Lipid profile (TC, HDL-C, TG, LDL-C, Non-HDL-C).

3. Treatment Indications (Who Needs a Statin?)

This is one of the most high-yield areas for the CDE exam. Statin therapy is recommended based on risk category, not just baseline LDL levels.

A. Secondary Prevention (High Risk)

  • Indication: Any person with diabetes and Clinical Cardiovascular Disease (CVD).

  • Action: Start Statin.

B. Primary Prevention (Type 2 Diabetes)

  • Age 40 years: Start Statin (regardless of baseline LDL).

  • Age < 40 years: Start Statin IF one of the following is present:

    • Microvascular complications (retinopathy, kidney disease, neuropathy).

    • Assessment warrants therapy based on other guidelines (e.g., Familial Hypercholesterolemia).

C. Primary Prevention (Type 1 Diabetes)

  • Age 40 years: Start Statin.

  • Age < 40 years: Start Statin IF:

    • Duration of diabetes years AND age years.

    • Microvascular complications are present.

4. Treatment Targets

Once a patient is on a statin, you treat to a specific target.

  • Primary Target:

    • LDL-C 2.0 mmol/L

    • OR 50% reduction from baseline LDL-C.

  • Alternate Targets (if LDL is accurate):

    • Non-HDL-C mmol/L.

    • Apolipoprotein B (ApoB) g/L.

5. Pharmacotherapy Management

A. Statins (HMG-CoA Reductase Inhibitors)

  • First-line therapy.

  • Pregnancy: Contraindicated. Women of childbearing potential must use reliable contraception or stop statins before conception.

B. Second-Line Agents If targets are not met with maximally tolerated statin doses:

  • Ezetimibe: Can be added to statins.

  • PCSK-9 Inhibitors (e.g., Evolocumab, Alirocumab): Injectable agents that dramatically lower LDL; indicated if targets are missed despite statin + ezetimibe, or for Familial Hypercholesterolemia.

C. Hypertriglyceridemia

  • Lifestyle: Weight loss, optimal glycemic control, and restricting alcohol/refined sugars are key.

  • Fibrates:

    • Generally NOT recommended for reducing CVD risk (evidence from FIELD and ACCORD-Lipid trials was weak).

    • Exception: Use fibrates to prevent pancreatitis if Triglycerides are severe ( mmol/L).

6. 2018 Diabetes Canada Clinical Practice Guidelines Recommendations

Key takeaways from the “Recommendations” section.

  1. Statin Initiation: Recommended for:

    • Adults with clinical CVD [Grade A, Level 1].

    • Adults age 40 years [Grade A, Level 1 for T2D; Grade D for T1D].

    • Adults age < 40 years with microvascular complications or long duration (>15 yrs duration and age >30) [Grade D, Consensus].

  2. Targets: The primary goal is LDL-C consistently mmol/L or a reduction from baseline [Grade D, Consensus].

  3. Fibrates: Fibrate therapy should not be used routinely for the purpose of reducing CVD risk [Grade A, Level 1A].

  4. Severe Hypertriglyceridemia: In individuals with TG mmol/L, a fibrate may be used to reduce the risk of pancreatitis [Grade D, Consensus].

  5. Combination Therapy: For those not at LDL target, ezetimibe or PCSK9 inhibitors may be used [Grade A/D depending on drug].

Reference:

Mancini GBJ, Hegele RA, Leiter LA. Dyslipidemia. Canadian Journal of Diabetes. 2018;42:S178-S185. doi:10.1016/j.jcjd.2017.10.019